KAHTNU Surgical Receives $2M Funding: To Expand Worldwide Sales

Partners with U.K. Ortho Consulting Group for Global Sales Expansion

July 15, 2020

KAHTNU Surgical, a U.S. medical technology company based in Alaska, announced today it had completed a $2.15 million Series A round of financing led by Kinetic Medical Co., Ltd. The investment will help KAHTNU Surgical aggressively expand worldwide sales and marketing efforts as well as broaden and accelerate product development for spine and orthopedic surgeons.

KAHTNU Surgical provides a range of products for spine and orthopedic surgery. Most notably KAHTNU Surgical provides the KASILOF Cervical Plate, CHENA-C PEEK Spacer and TALKEETNA Pedicle Screw systems for spine surgery. “This funding will accelerate the company’s ability to establish quality sales channels in the U.S. and aggressively expand our product development capabilities,” says Craig Wilcox, President and CEO. “KAHTNU Surgical is committed to product development that harnesses existing and emerging technologies to improve outcomes for spine and orthopedic surgeons and their patients,” notes Wilcox.

KAHTNU Surgical also announced a partnership with United Kingdom-based Ortho Consulting Group Ltd (OCG) to establish and support KAHTNU Surgical sales channels outside the United States. “Ortho Consulting Group’s team of industry experts brings a broad array of capabilities to KAHTNU, driving our European, and Outside U.S. KOL selection process, marketing, sales, distribution, training, logistics and operations. We are delighted to partner with OCG,” says Wilcox.

Andrew Dubowski, Ortho Consulting Group Commercial Director, adds: “We are thrilled to partner with KAHTNU Surgical. The commitment they show to provide high quality/cost-effective products in the spine industry makes this an exciting addition to our client portfolio. We are looking forward to helping KAHTNU Surgical grow globally.” More information on Ortho Consulting Group is at Orthocg.com.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version